Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
FBR Reiterates Advaxis (ADXS) at 'Outperform' Following Positive AXAL Combo Study with Durvalumab Data
March 29, 2016 11:46 AM EDTFBR & Co. reaffirms Advaxis, Inc. (Nasdaq: ADXS) at Outperform with a price target of $34 after the company... More
